A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...
Study links higher expression of the gene PROX1 to aggressive change in prostate tumor cells; FDA-approved class of drugs can disable PROX1 ANN ARBOR, Michigan — Researchers at the University of ...
Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological explanation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results